Retrophin: Phase 3 FORT Study Fails To Meet Endpoints - Quick Facts

(RTTNews) - Retrophin, Inc. (RTRX), a biopharmaceutical company, said the Phase 3 Study evaluating fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration failed to meet primary endpoint, as well as secondary endpoint. Fosmetpantotenate was generally safe and well-tolerated in the study.

Retrophin said the company will discuss with study investigators to decide the next steps for the FORT Study, including the ongoing open-label extension of the study.

Retrophin said it remains focused on advancing two pivotal Phase 3 programs evaluating sparsentan.